Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities

Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alp...

Full description

Saved in:

Bibliographic Details
Main Author:	Abd Aziz, Noraini
Format:	Thesis
Language:	English
Published:	2013
Subjects:	Protease inhibitors - Therapeutic use Cancer - Chemotherapy
Online Access:	http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-upm-ir.48690
record_format	uketd_dc
spelling	my-upm-ir.486902016-10-14T08:08:09Z Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities 2013-11 Abd Aziz, Noraini Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs. Protease inhibitors - Therapeutic use Cancer - Chemotherapy 2013-11 Thesis http://psasir.upm.edu.my/id/eprint/48690/ http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf application/pdf en public masters Universiti Putra Malaysia Protease inhibitors - Therapeutic use Cancer - Chemotherapy
institution	Universiti Putra Malaysia
collection	PSAS Institutional Repository
language	English
topic	Protease inhibitors - Therapeutic use Cancer - Chemotherapy
spellingShingle	Protease inhibitors - Therapeutic use Cancer - Chemotherapy Abd Aziz, Noraini Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
description	Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs.
format	Thesis
qualification_level	Master's degree
author	Abd Aziz, Noraini
author_facet	Abd Aziz, Noraini
author_sort	Abd Aziz, Noraini
title	Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_short	Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_full	Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_fullStr	Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_full_unstemmed	Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_sort	effects of bortezomib on hif-1 and hif-2 transcriptional activities
granting_institution	Universiti Putra Malaysia
publishDate	2013
url	http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf
_version_	1747811992592187392

Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities

Similar Items